Emil Billbäck Joins the ATiO Advisory Board

We are pleased to share that Emil Billbäck joined the Advisory Board of the ATiO Foundation in June 2024, bringing with him more than 25 years of international leadership in life sciences, regenerative medicine, and biopharmaceutical innovation. His strategic insight and global experience are already proving invaluable as ATiO continues to advance its mission in cutting-edge orthopaedic therapies.

A Proven Leader in Regenerative Healthcare

Born in 1970, Emil Billbäck has built a distinguished career in the life sciences and medtech sectors, holding senior roles across Sweden, Germany, and the United States. Since March 2018, he has served as Chief Executive Officer of BONESUPPORT AB, an orthobiologics company focused on bone regeneration. Under his leadership, BONESUPPORT has expanded its international presence and driven innovation in musculoskeletal treatments.

Prior to joining BONESUPPORT, Billbäck was Chief Commercial Officer at BSN Medical, where he led global commercialization efforts in wound care and orthopaedics. He has also held key operational and strategic roles at AstraZeneca, Beiersdorf, and served as a Senior Strategic Advisor at ESSITY.

His academic foundation is in Business Administration (B.Sc.) from Karlstad University, and his broad industry experience combines scientific innovation with commercial strategy and international market development.

Board Experience and Global Perspective

In addition to his executive roles, Billbäck has served on several corporate and advisory boards, including as a current Board Member of Doctrin, a digital health company, and previously as a Board Member of ATOS Medical, a global leader in ENT medical devices. His ability to navigate both operational leadership and governance roles makes him a valuable advisor to mission-driven organizations like ATiO.

Having lived and worked in the United States and Germany, Billbäck brings a uniquely international perspective to his work – an asset as ATiO continues to expand its global partnerships and research collaborations.

Supporting ATiO’s Vision for the Future

At the ATiO Foundation, Billbäck’s wide-ranging expertise strengthens our mission to translate advanced science into real-world musculoskeletal therapies. His track record in leading organizations through clinical development, commercial strategy, and global expansion aligns closely with ATiO’s goals of accelerating innovation and bridging the gap between research, industry, and patient care.

His appointment to the Advisory Board in June 2024 marked an exciting milestone as ATiO deepens its collaborations with leading institutions such as the Osteoarthritis Research Society International (OARSI) and others across Asia, Europe, and North America.

We are honored to have Emil Billbäck as a member of the ATiO Advisory Board and look forward to the continued impact of his leadership in shaping the future of regenerative and orthopaedic care.